A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IMM-H014 Sand the Effects of Food on Pharmacokinetics in Healthy Subjects
Latest Information Update: 16 Apr 2025
At a glance
- Drugs IMM H014 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Changchun Intellicrown Pharmaceutical
- 11 Apr 2025 Planned End Date changed from 1 Dec 2024 to 1 Aug 2025.
- 11 Apr 2025 Planned primary completion date changed from 1 Jul 2024 to 1 Jun 2025.
- 29 Jan 2024 New trial record